Clinical trial
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination…
NCT00424840 · University of Massachusetts, Worcester, Other · Terminated
Key facts
| NCT number | NCT00424840 |
|---|---|
| Title | Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy |
| Official title | Phase I/II Study to Evaluate the Efficacy and Safety of Combination Chemotherapy With Carboplatin, Bortezomib and Bevacizumab as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer |
| Lead sponsor | University of Massachusetts, Worcester, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry Genentech, Inc. |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Bortezomib 1.8 mg/m2, Carboplatin AUC 6, Bevacizumab, Taxotere |
| Enrollment | 12 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2014 |
| Completion | Mar 1, 2014 |
| First posted | Jan 22, 2007 |
| Last update posted | Feb 1, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: